Coexpression of IL-6 and TNF-α: Prognostic significance on breast cancer outcome

Neoplasma

Volumn 61, Issue 2, 2014, Pages 205-212

  Tripsianis, G ^a   Papadopoulou, E ^a   Anagnostopoulos, K ^a   Botaitis, S ^a   Katotomichelakis, M ^a   Romanidis, K ^a   Kontomanolis, E ^a   Tentes, I ^a   Kortsaris, A ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Breast cancer; IL 6; Metastasis; Prognosis; Survival; TNF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERLEUKIN 6; PROGESTERONE RECEPTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME;

IL-6, TNF-Α, BREAST CANCER, PROGNOSIS, METASTASIS, SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893156426     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_026     Document Type: Article

References (51)

1. ELSTON CW, ELLIS IO, PINDER SE Pathological prognostic factors in breast cancer. Crit Rev Oncol Haematol 1999; 31: 209-223. http://dx.doi.org/10.1016/S1040-8428(99)00034-7
2. ISAACS C, STEARNS V, HAYES DF New prognostic factors for breast cancer. Semin Oncol 2001; 28: 53-67. http://dx.doi.org/10.1016/S0093-7754(01)90045-4
3. DUFFY MJ Urokinase plasminogen activator and its inhibitor, PAI-1, as prognos-tic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002; 48: 1194-1197.
4. BOSL GJ, MOTZER RJ Testicular germ-cell cancer. N Engl J Med 1977; 337: 242-251. http://dx.doi.org/10.1056/NEJM199707243370406
5. FISHER PM, HANCOCK BW Gestational trophoblastic disease and their treat-ment. Cancer Treat Rev 1997; 23: 1-16. http://dx.doi.org/10.1016/S0305-7372(97)90017-7
6. RUSTIN GJS Use of CA 125 to assess response to new agents in ovarian cancer trials, J Clin Oncol 2003; 21(10 Suppl): 187s-193s.
7. DUFFY MJ Carcinoembryonic antigen as a marker for colorectal cancer: is it clin-ically useful? Clin Chem 2001; 47: 624-630.
8. PARKER C Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-106. http://dx.doi.org/10.1016/S1470-2045(04)01384-1
9. DUFFY MJ Serum tumor markers in breast cancer: are they of clinical value? Clinical Chemistry 2006; 52(3): 345-351. http://dx.doi.org/10.1373/clinchem.2005.059832
10. PAPADOPOULOU E, TRIPSIANIS G, ANAGNOSTOPOULOS K, TENTES I, KAKOLYRIS S et al. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma 2008; 55: 113-121.
11. EBELING FG, STIEBER P, UNTCH M, NAGEL D, KONECNY GE et al. Se-rum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002; 22: 1217-1222. http://dx.doi.org/10.1038/sj.bjc.6600248
12. MOLINA R, FILELLA X, ALICARTE J, ZANON G, PAHISA J et al. Prospec-tive evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anti-cancer Res 2003; 23: 1035-1042.
13. CARNEY WP, NEUMAN R, LIPTON A, PRICE C Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003; 49: 1579-1598. http://dx.doi.org/10.1373/49.10.1579
14. KNUPFER H, PREISS R Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007; 102:129-135. http://dx.doi.org/10.1007/s10549-006-9328-3
15. CHAVEY C, BIBEAU F, GOURGOU-BOURGADE S, BURLINCHON S, BOISSIERE F et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007; 9: R15. http://dx.doi.org/10.1186/bcr1648
16. NICOLINI A, CARPI A, ROSSI G Cytokines in breast cancer. Cytokine Growth Factor Rev 2006; 17: 325-337. http://dx.doi.org/10.1016/j.cytogfr.2006.07.002
17. KINDER M, CHISLOCK E, BUSSARD K, SHUMAN L, MASTRO A Metas-tatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 2008; 314: 173-183. http://dx.doi.org/10.1016/j.yexcr.2007.09.021
18. SALGADO R, JUNIUS S, BENOY I, VAN DAM P, VERMEULEN P et al. Cir-culating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103: 642-646. http://dx.doi.org/10.1002/ijc.10833
19. LOCKSLEY RM, KILLEEN N, LENARDO MJ The TNF and TNF receptor su-perfamilies: integrating mammalian biology. Cell 2001; 104: 487-501. http://dx.doi.org/10.1016/S0092-8674(01)00237-9
20. MACEWAN DJ TNF receptor subtype signalling: differences and cellular con-sequences. Cell Signal 2002; 14: 477-492. http://dx.doi.org/10.1016/S0898-6568(01)00262-5
21. BALKWILL F Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135-141. http://dx.doi.org/10.1016/S1359-6101(01)00020-X
22. VILCEK J, LEE TH Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991; 266: 7313-7316.
23. TRIPSIANIS G, PAPADOPOULOU E, BOTAITIS S, ANAGNOSTOPOULOS K, TENTES I et al. Diagnostic and prognostic significance of serum IL-6 levels in breast cancer. JP Journal of Biostatistics 2012; 1-2: 59-77.
24. PAPADOPOULOU E, TRIPSIANIS G, ANAGNOSTOPOULOS K, TENTES I, KAKOLYRIS S et al. Significance of serum tumor necrosis factor-alpha and its inter-action with HER-2 codon 655 polymorphism on breast cancer outcome. Int J Biol Markers 2010; 25: 126-135.
25. BLOOM HJG, RICHARDSON WW Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-377. http://dx.doi.org/10.1038/bjc.1957.43
26. UNION INTERNATIONALE CONTRE LE CANCER (UICC). TNM classifica-tion of malignant tumors (4th ed). Berlin: Springer Verlag, 1992.
27. LIN WW, KARIN M A cytokine-mediated link between innate immunity, in-flammation, and cancer. J Clin Invest 2007; 117: 1175-1183. http://dx.doi.org/10.1172/JCI31537
28. THOMSON AW, LOTZE MT The cytokine handbook (4th ed). London: Aca-demic Press, 2003.
29. GRIVENNIKOV SI, GRETEN FR, KARIN M Immunity, inflammation, and cancer. Cell 2010; 140: 883-899. http://dx.doi.org/10.1016/j.cell.2010.01.025
30. GRIVENNIKOV SI, KARIN M Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11-19. http://dx.doi.org/10.1016/j.cytogfr.2009.11.005
31. AGGARWAL BB, VIJAYALEKSHMI RV, SUNG B Targeting infl ammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009; 15: 425-430. http://dx.doi.org/10.1158/1078-0432.CCR-08-0149
32. GRIVENNIKOV SI, KARIN M Inflammatory cytokines in cancer: tumor necro-sis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70(Suppl 1): i104-i108. http://dx.doi.org/10.1136/ard.2010.140145
33. RAO VSR, DYER CE, JAMEEL JKA, DREW PJ, GREENMAN J Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncology Reports 2006; 15: 179-185.
34. AL-HASSAN AA, AL-GHURABI BH, AL-KARKHI IH Prognostic value of proinflammatory cytokines in breast cancer. J Biomol Res Ther 2012; 1:104.
35. ALSUHAIL R Serum level of interleukin 6 and tumor necrosis factor in Iraqi breast cancer patients. MMJ 2008; 7: 34-36.
36. RAVISHANKARAN P, KARUNANITHI R Clinical significance of preopera-tive serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 2011; 9: 18. http://dx.doi.org/10.1186/1477-7819-9-18
37. ALI HQ, MAHDI NK, and AL-JOWHER MH Serum ig and cytokine levels in women with breast cancer before and after mastectomy. Medical Journal of Islamic World Academy of Sciences 2012; 20: 121-129.
38. AYDIN Y, KAPLAN I, BILEN Y, BULUT C, GENÇ F et al. Plasma levels of IL-6 and TNF-α in patients with esophageal cancer. Turk J Med Sci 2012; 42: 762-767.
39. MOORE RJ, OWENS DM, STAMP G, ARNOTT C, BURKE F et al. Mice defi-cient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-831. http://dx.doi.org/10.1038/10552
40. BALKWILL F Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135-141. http://dx.doi.org/10.1016/S1359-6101(01)00020-X
41. BALKWILL F Tumor necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-371. http://dx.doi.org/10.1038/nrc2628
42. BROMBERG JF, WRZESZCZYNSKA MH, DEVGAN G, ZHAO Y, PESTELL RG et al. Stat3 as an oncogene. Cell 1999; 98: 295-303. http://dx.doi.org/10.1016/S0092-8674(00)81959-5
43. ARA T., DECLERCK Y Interleukin-6 in bone metastasis and cancer progres-sion. Eur J Cancer 2010; 46: 1223-1231. http://dx.doi.org/10.1016/j.ejca.2010.02.026
44. LIU Y, FUCHS J, LI CH, LIN J IL-6, a risk factor for hepatocellular carcinoma. FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular can-cer cells, Cell Cycle 2010; 9: 3423-3427. http://dx.doi.org/10.4161/cc.9.17.12946
45. YU H, PARDOLL D, JOVE R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809. http://dx.doi.org/10.1038/nrc2734
46. BOLLRATH J, GRETEN FR IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumor promotion and metastasis. EMBO Rep 2009; 10: 1314-1319. http://dx.doi.org/10.1038/embor.2009.243
47. KIM SY, KANG JW, SONG X, KIM BK, YOO YD et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of nonstem cancer cells into cancer stem-like cells, Cell Signal 2013; 25: 961-969. http://dx.doi.org/10.1016/j.cellsig.2013.01.007
48. ALVAREZ B, QUINN LS, BUSQUETS S, QUILES MT, LOPEZ-SORIANO FJ et al. Tumor necrosis factor-alpha exerts interleukin-6-dependent and independent ef-fects on cultured skeletal muscle cells. Biochim Biophys Acta 2002; 1542(1-3): 66-72. http://dx.doi.org/10.1016/S0167-4889(01)00167-7
49. SHARMA R, ANKER SD Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002; 85: 161-171. http://dx.doi.org/10.1016/S0167-5273(02)00244-9
50. KAYACAN O, KARNAK D, BEDER S, GÜLLÜ E, TUTKAK H et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol 2006; 29: 328-335. http://dx.doi.org/10.1097/01.coc.0000221300.72657.e0
51. BEN-BARUCH A Host microenvironment in breast cancer development: In-flammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003; 5: 31-36. http://dx.doi.org/10.1186/bcr690